- €7.50bn
- €7.24bn
- €3.57bn
- 94
- 28
- 82
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.6 | ||
| PEG Ratio (f) | 0.31 | ||
| EPS Growth (f) | 38.64% | ||
| Dividend Yield (f) | 1.47% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.79 | ||
| Price to Tang. Book | 7.78 | ||
| Price to Free Cashflow | 56.4 | ||
| Price to Sales | 2.1 | ||
| EV to EBITDA | 8.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.94% | ||
| Return on Equity | 8.89% | ||
| Operating Margin | 13.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 2,686.2 | 2,748.6 | 3,156.4 | 3,306.4 | 3,574.5 | 3,729.46 | 3,945.57 | 5.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +66.92 | -2.45 | +9.29 | -38.47 | +22.5 | +60.68 | +6.43 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Directors
- Marc de Garidel CHM (63)
- David Loew CEO (54)
- Antoine Flochel VCH (55)
- Aymeric le Chatelier CFO (51)
- Regis Mulot CHO (54)
- Dominique Laymand EVP (65)
- Francois Garnier EVP (58)
- Dominique Bery EVP (49)
- Stewart Campbell EVP
- Benoit Hennion EVP (44)
- Steven Hildemann EVP
- Philippe Lopes-Fernandes EVP
- Howard Mayer EVP (58)
- Aidan Murphy EVP (54)
- Richard Paulson EVP (53)
- Mari Scheiffele EVP
- Gwenan White EVP
- Anne Beaufour DRC (56)
- Henri Beaufour DRC (55)
- Philippe Bonhomme DRC (50)
- Laetitia Ducroquet DRC (41)
- Michele Ollier DRC (63)
- Jean-Marc Parant DRC (60)
- Carol Xueref DRC (64)
- Margaret Liu IND (64)
- Paul Sekhri IND (63)
- Carol Stuckley IND (66)
- Piet Wigerinck IND (56)
- Karen Witts IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 28th, 1998
- Public Since
- December 6th, 2005
- No. of Employees
- 5,358
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Euronext - Paris- Shares in Issue
- 82,709,453
- Address
- 65 Quai Georges Gorse, BOULOGNE-BILLANCOURT, 92100
- Web
- https://www.ipsen.com/
- Phone
- +33 158335000
- Auditors
- Deloitte & Associes
Upcoming Events for IPN
Ipsen SA Annual Shareholders Meeting
Dividend For IPN.PA - 1.4000 EUR
Half Year 2025 Ipsen SA Earnings Release
Similar to IPN
AB Science SA
Euronext - Paris
Advicenne SA
Euronext - Paris
Aelis Farma SA
Euronext - Paris
Boiron SA
Euronext - Paris
DBV Technologies SA
Euronext - Paris
FAQ
What is the Ipsen SA share price?
As of Today at 21:22 UTC, shares in Ipsen SA are trading at €90.70. This share price information is delayed by 15 minutes.
How has the Ipsen SA share price performed this year?
Shares in Ipsen SA last closed at €90.70 and the price had moved by -14.76% over the past 365 days. In terms of relative price strength the Ipsen SA share price has underperformed the FTSE Global All Cap Index by -16.26% over the past year.
What are the analyst and broker recommendations for Ipsen SA?
The overall consensus recommendation for Ipsen SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ipsen SA dividend yield?
The Ipsen SA dividend yield is 1.54% based on the trailing twelve month period.
Does Ipsen SA pay a dividend?
Last year, Ipsen SA paid a total dividend of €1.40, and it currently has a trailing dividend yield of 1.54%.Looking ahead, shares in Ipsen SA are due to go ex-dividend on 2025-06-04 and the next dividend pay date is 2025-06-06.
When does Ipsen SA next pay dividends?
Ipsen SA are due to go ex-dividend on 2025-06-04 and the next dividend pay date is 2025-06-06. The historic dividend yield on Ipsen SA shares is currently 1.54%.
How do I buy Ipsen SA shares?
To buy shares in Ipsen SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ipsen SA?
As of the previous close price of €90.70, shares in Ipsen SA had a market capitalisation of €7.50bn.
Where are Ipsen SA shares listed?
Here are the trading details for Ipsen SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: IPN
What kind of share is Ipsen SA?
Based on an overall assessment of its quality, value and momentum Ipsen SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ipsen SA share price forecast for 2025?
The analyst consensus target price for shares in Ipsen SA is €123.60. That is 36.27% above the last closing price of €90.70.
Analysts covering Ipsen SA currently have a consensus Earnings Per Share (EPS) forecast of €10.35 for the next financial year.
Find out moreWhat is the trend in the Ipsen SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ipsen SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -19.73%.
As of the last closing price of €90.70, shares in Ipsen SA were trading -17.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ipsen SA PE Ratio?
The Ipsen SA PE ratio based on its reported earnings over the past 12 months is 8.6. The shares last closed at €90.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ipsen SA?
Ipsen SA's management team is headed by:
- Marc de Garidel - CHM
- David Loew - CEO
- Antoine Flochel - VCH
- Aymeric le Chatelier - CFO
- Regis Mulot - CHO
- Dominique Laymand - EVP
- Francois Garnier - EVP
- Dominique Bery - EVP
- Stewart Campbell - EVP
- Benoit Hennion - EVP
- Steven Hildemann - EVP
- Philippe Lopes-Fernandes - EVP
- Howard Mayer - EVP
- Aidan Murphy - EVP
- Richard Paulson - EVP
- Mari Scheiffele - EVP
- Gwenan White - EVP
- Anne Beaufour - DRC
- Henri Beaufour - DRC
- Philippe Bonhomme - DRC
- Laetitia Ducroquet - DRC
- Michele Ollier - DRC
- Jean-Marc Parant - DRC
- Carol Xueref - DRC
- Margaret Liu - IND
- Paul Sekhri - IND
- Carol Stuckley - IND
- Piet Wigerinck - IND
- Karen Witts - IND